I am a Medical Oncology Consultant for the Gastrointestinal Oncology Service at University College London Hospitals NHS Foundation Trust and Honorary Associate Professor at the UCL Cancer Insitute. I treat oesophageal, stomach, small bowel, colorectal and hepatobiliary cancers, as well as cancers of unknown primary. I am the UCLH Clinical Lead for the Cancer of Unknown Primary (CUP) Service and the Acute Oncology Service.

My research interests include immunotherapy for GI malignancies and Cancer of Unknown Primary, with focus on clinical trials and translational research of these cancers. I am Chief Investigator or Principal Investigator for a number of  GI or CUP immuno-oncology Phase 2 and 3 trials, including KEYNOTE 177, KEYNOTE 859, KEYNOTE 811, KEYNOTE 975,  VESTIGE, POLEM and CUPISCO.

I am Chair of the NCRI MUO-CUP Workstream as part of the Living With and Beyond Cancer CSG, and a member of the NCRI Colorectal Advanced and Adjuvant Disease Subgroup. I am the Principal Investigator of the UCL-UCLH GI + CUP Cancer Translational Research Biobank and a collaborator with the GI Oncology and CUP subgroups at the UCL Cancer Institute and Francis Crick Institute. I am a member of ASCO, ESMO and the Association of Cancer Physicans (UK).

I strongly believe in clinicians being educators and enjoy teaching oncology to UCL medical students, oncology and non-oncology junior trainees. I also give talks nationally and abroad at conferences and other hospitals to share best practice and future perspectives in the fields of GI oncology research, CUP, immunotherapy and novel trial designs.

To make an appointment or enquiry please contact my secretary Alanna Sarwar on asarwar@theloc.com or +44207 317 2659.

• Gastrointestinal Oncology - oesophageal, stomach, hepatobiliary and bowel cancers
• Cancer of Unknown Primary
• Acute Oncology
• Chemotherapy
• Targeted therapy
• Immunotherapy
• Clinical Trials

• Immunotherapy
• Gastrointestinal Oncology Research 
• Cancer of Unknown Primary Research 
• Molecular Profiling with solid and liquid biopsies
• Biomarker Driven Clinical Trial Design and Implementation

George Mikhaeel is a Professor of Radiation Oncology at King’s College London and Consultant Clinical Oncologist at Guy’s & St Thomas’ NHS Foundation Trust since 2001. He specialises in the treatment of lymphoma with both chemotherapy and radiotherapy and has extensive experience in advanced radiotherapy techniques for haematological malignancies.

Professor Mikhaeel’s research has resulted in new ways of treating lymphoma patients with radiotherapy, harnessing the benefits of advances in radiotherapy technology and advances in imaging. An example of new treatments is combining an innovative arc technique and deep inspiration breath-hold (DIBH) with image-guided delivery of treatment to improve the accuracy of targeting radiation and reduce dose to healthy tissues.

His clinical practice is focused only on haematological malignancies which are less common and require a high level of specialisation and substantial clinical experience, having practised in this field for more 20 years. Professor Mikhaeel has lectured in more than 15 countries and has numerous publications in the field including four influential international guidelines.

He is a founding member of the International Lymphoma Radiation Oncology Group (ILROG) and a member of its steering and executive committees. Professor Mikhaeel also chairs the haematology track for the American Society of Radiation Oncology (ASTRO) annual meeting scientific committee and a reviewer for the European Society of Radiation Oncology (ESTRO). Nationally, he is the chair of the UK Lymphoma Radiotherapy Group (UK-LRG) steering committee.

• Radiotherapy
• Chemotherapy

• Haematological malignancies

Vinod Mullassery is a Consultant Clinical Oncologist specialising in the management of prostate and bladder cancers.

He received his oncology training at University College Hospital, London, Great Ormond Street Hospital, London and Mount Vernon Cancer Centre, London

Vinod undertook a nationally funded post CCT fellowship at Mount Vernon Cancer Centre, gaining expertise in modern radiotherapy techniques. He was visiting Brachytherapy Fellow at University of Leuven, Belgium and at University of California, Los Angeles, USA.

He treats solid tumours with radiotherapy, chemotherapy, hormones and biological therapies.

He is actively involved in research and clinical trials and is principal investigator on number of trials.He also led the implementation of image guided interstitial brachytherapy programme for cervical cancer.

He is actively involved in teaching both at undergraduate and postgraduate level and has previously held the position of the College Tutor and the Post graduate faculty lead for Clinical Oncology at Guys and St Thomas' Hospital.

Diseases, Medical Tests and Treatments

Radiotherapy for prostate cancer and Bladder cancer

Hormone treatment for prostate cancer

SABR for oligo metastatic disease

Research Interests-

high dose rate brachytherapy

cancer imaging

Dr Jonathan Shamash is a Consultant Oncologist and is the Lead in Acute Oncology at St Bartholomew’s Hospital and has a further NHS base at Queen’s Hospital, Romford. Dr Shamash also sees patients privately, including at Leaders in Oncology Care. He graduated from the University of Edinburgh in 1987 and then undertook post graduate training in London, gaining an MD in in-vitro modelling of lymphoma.

Dr Shamash sub-specialises in genito-urinary cancers and thoracic malignancies. He has a special interest in managing complex oncology problems and delivering intensive treatments, including high dose Interleukin-2 and high does chemotherapy in testicular cancer. . Dr Shamash also chairs the supra-regional germ cell tumour multidisciplinary meeting and is a member of the NCRI testis clinical studies group. He leads various clinical studies in the management of testicular and prostate cancer and has published widely.

Dr Rebecca Kristeleit is a Clinical Senior Lecturer and Consultant Medical Oncologist at UCL/UCLH. She specialises in the treatment of gynaecological cancers such as cervical cancer, endometrial cancer, and ovarian cancer. She also has a specialist interest in drug development as well and is leading several clinical trials of novel agents relevant to gynaecological malignancies including PARP inhibitors.

Dr Kristeleit qualified in medicine from St Andrew’s and Manchester Universities including eight months at the University of Lausanne (Switzerland) on an Erasmus scholarship. Following general medical training in London, she undertook my medical oncology training at The Royal Marsden Hospital and a CRUK-funded research fellowship at the Institute of Cancer Research. Subsequently, Dr Kristeleit spent a year as a senior research fellow on the Drug Development Unit at the Royal Marsden Hospital gaining specialist experience in the design and conduct of early phase clinical trials and translational medicine.

Dr Kristeleit's research work, as part of the UCLH gynaecological oncology team, Clinical Research Facility at UCLH and the UCL Cancer Institute, is focused on the development of early-phase clinical trials and translational research to identify and evaluate innovative treatment strategies for gynaecological malignancies as well as other solid tumours.

• Cervical cancer
• Endometrial cancer
• Ovarian cancer

• Cervical cancer
• Endometrial cancer
• Ovarian cancer

Dr Anita Mitra is a Consultant in Clinical Oncology based at University College London Hospitals NHS Foundation Trust and she also sees patients privately. She specialises in the treatment of urological cancers including prostate, bladder, testicular and advanced penile cancer.

• Radiotherapy

• Prostate Cancer

Deborah Enting is a Consultant Medical Oncologist at Guy's and St Thomas' NHS Foundation Trust and an Honorary Senior Lecturer at King's College London.

She undertook her medical training at the University of Groningen in The Netherlands and trained in Medical Oncology at Guy's and St George's Hospitals. She was a research fellow at the Department of Immunobiology at King's College London and in collaboration with colleagues of the Translational Oncology Urology Research (TOUR) group at KCL she works on tumour immune surveillance and bladder cancer research.

Deborah is a Medical Oncologist specialising in the treatment of Urological Cancers and the systemic treatment (chemotherapy, immunotherapy and targeted therapies) for bladder, prostate, kidney and testicular cancers. She is a national lead on a number of clinical trials including the IRONMAN prostate cancer registry study.

• Bladder cancer
• Prostate cancer
• Kidney cancer
• Testicular cancer

• Bladder cancer
• Prostate cancer
• Kidney cancer
• Testicular cancer

Dr Asad Qureshi is a Consultant Clinical Oncologist at Guy’s and St Thomas’ NHS Foundation Trust. In his NHS and private practice, he specialises in the treatment of upper and lower gastro-intestinal and non-melanoma skin cancers: Oesophageal Cancer, Stomach Cancer, Colon Cancer, Rectal Cancer, Radiotherapy for non-melanomatous skin cancer, Chemotherapy and SABR. Dr Qureshi is the Clinical Lead for out-patients in the Cancer Centre at Guy’s Hospital, London and is a member of the Senior Oncology Management Team. He is also the Clinical Oncology and Radiotherapy Audit Lead and the Clinical Oncology Oesophago-gastric lead.

He trained at St Bartholomew’s and The Royal London Hospitals medical schools where he gained a BSc in neurosciences. He completed his specialist training in Clinical Oncology at a number of specialist departments in London, including Guy’s and St Thomas’ Hospital, Charing Cross Hospital, St Bartholomew’s Hospital and The Royal Marsden Hospital. During his training spent two years working in the Imaging Sciences Laboratories at Kings College London, and the Centre for Medical Image Computing at University College London assessing novel radiotherapy techniques for the treatment of mobile tumours. Dr Qureshi plays an active role in research and is a Principle Investigator on a number of national clinical trials. His research interests include Stereotactic Radiotherapy (SABR), Image-guided Radiotherapy (IGRT) and dose escalation of radiotherapy and he has published a number of papers in this field.Dr Qureshi is committed to medical education. He is a clinical and educational supervisor for Clinical Oncology trainees at Guy’s and St Thomas’ NHS Foundation Trust. He is also a Medical Supervisor for radiographers on prescribing courses.

• External Beam Radiotherapy (IMRT and IGRT)
• Chemotherapy
• Radiotherapy
• Stereotactic Radiotherapy (Including CyberKnife)

• Colorectal Cancer
• Anal Cancer
• Oesophageal Cancer
• Gatro-intestinal Cancers
• Stomach Cancer

Dr Anne Armstrong is a well-respected Consultant Oncologist with HCA Healthcare and Guy's and St. Thomas' NHS Foundation Trust in London where she is the Head of Medical Oncology, along with being the lead for Systemic Treatment of Breast Cancer in South East London.

She graduated with a degree in Psychology and returned to university to study Medicine at the renowned Imperial College London. She completed her medical oncology training at numerous centres of excellence, including the Royal Marsden Hospital and Hammersmith Hospital. Following this she completed pioneering research into the molecular genetics of breast and pancreatic cancer and was awarded a PhD. In 2005 she was appointed her first Consultant post. She remains heavily involved in research, being appointed as chief investigator and of numerous breast cancer trials.

• Chemotherapy
• Hormonal Therapy
• Endocrine Therapy

• Breast Cancer

I am a Clinical Reader and Consultant Medical Oncologist at King’s College London and Guy’s and St Thomas’ NHS Foundation Trust. I graduated from University of Oxford in pre-clinical medicine in 1998 and from Imperial College London in Clinical Medicine in 2001. After seven years of training in medicine and oncology I took three years out of my clinical training to carry out a PhD in cancer immunotherapy from King’s College London. My PhD studies were focused on genetically modifying cells for cancer immune therapy with a technique called CAR T Cell therapy. After being awarded my PhD in 2011 I returned to complete my clinical training in medical oncology. I also continued my laboratory research with a Clinical Lecturership from the National Institute for Health Research (NIHR). In 2013 I was awarded a Medical Research Council Clinician Scientist Fellowship to pursue a career at the interface between clinical practice in medical oncology and novel immune therapy research and development. I have published over twenty five peer reviewed papers. 

My research group at King's College London studies approachs to optimise personalised cell-based immune therapies for solid tumour oncology. Through vital collaborations with colleagues at King's and across the UK we are also studying the impact of immune therapies, called checkpoint inhibitor therapies, on human immune responses to help us better understand our remarkable immune systems and develop better ways of predicting, preventing and treating the immune related side effects of these crucial new drugs. 

In my clinical practice I am a medical oncologist with a practice in malignant melanoma and Merkel Cell Carcinoma. I am a principal investigator in the Guy's Cancer Early Phase drug development team where I lead trials of new therapies or combinations in cancer patients. My particular focus is on cancer immune therapies, especially cellular therapies.   I lead for skin cancer research at Guy’s and St Thomas’ NHS Foundation Trust, am our programme director for cell therapies and chair our biological safety committee. 

I belive that quality cancer care is enhanced by bringing together skills in science and clinical practice. To do this well you need to be able to bring new treatments to patients and explain them well. 

I have a young family who take up most of my spare time. And a garden I am more roud of than perhapse I should be! 

.

• Oncolytic viral therapy
• T-VEC 

• Malignant melanoma
• Merkel cell carcinoma